Background: Although treatment-resistant and nontreatment-resistant depressed patients show structural brain anomalies relative to healthy controls, the difference in regional volumetry between these two groups remains undocumented.
INTRODUCTION
Treatment-resistant depression (TRD) occurs in 20-30% of depressed patients and leads to severe disability (Greden, 2001) . TRD is a condition in which the patients fail to respond to at least two trials scrutinized by neuroimaging studies (Konarski, McIntyre, Soczynska, Bottas, & Kennedy, 2006; Koolschijn, van Haren, Lensvelt-Mulders, HulshoffPol, & Kahn, 2009; Lorenzetti, Allen, Fornito, & Yucel, 2009; Price & Drevets, 2010) , fewer magnetic resonance (MR) studies have examined the brain structure in TRD versus nontreatment-resistant depression (non-TRD) (McIntyre et al., 2014 Glabus, & Goodwin, 1998; Shah, Glabus, Goodwin, & Ebmeier, 2002) .
Larger GM volumes have also been observed, notably in the temporal cortex regions, including the parahippocampus and amygdala (Li et al., 2010) , although this has not been constantly replicated (Zhou et al., 2011) . Further MR brain morphometry analysis is warranted given the scarcity of studies of these latter regions involved in emotional regulation.
Indeed, other MR modalities in TRD patients suggest changes in amygdala and related regions. Higher resting-state hippocampusamygdala blood flow was found in TRD patients compared with patients with non-TRD in a single photon emission computed tomography study (Hornig, Mozley, & Amsterdam, 1997) . Furthermore, arterial spin labelling perfusion magnetic resonance imaging (MRI) showed hyperperfusion in the TRD and chronically depressed patients, in the left subcortical regions (amygdala, putamen, and pallidum), together with the left dorsomedial prefrontal, left anterior cingulate cortex (ACC) (Duhameau et al., 2010) . Also, reduced functional connectivity within the left amygdala to anterior cingulate was reported when comparing TRD to non-TRD (Lui et al., 2011) . Reduced magnetization transfer ratio was observed in the amygdala-parahippocampal areas, caudate, anterior cingulate, and insula, in the right hemisphere, in the TRD group relative to healthy controls, but voxel-based morphometry (VBM) analyses did not reveal any morphological difference between these groups (Zhang et al., 2009 ).
The involvement of specific brain regions in TRD was furthermore suggested by the improvement of clinical conditions obtained through repetitive transcranial magnetic stimulation in dorsolateral prefrontal cortex (Paillère Martinot et al., 2011) or through deep brain stimulation in subcallosal cingulate (Holtzheimer & Mayberg 2010) .
Thus, the pathogenesis of TRD is still under debate; it could have structural (Li et al., 2010) and/or functional determinants being attributed to abnormal neural activity in multiple brain regions (Guo et al., 2011; Kumari et al., 2003; Lui et al., 2011) . Notably, abnormalities in limbic regions may play a role in the pathophysiology of treatment resistance (Hornig et al., 1997) , in the foreground of which is the amygdala-hippocampus complex.
There are a limited number of studies regarding the differences of brain morphometry between TRD and non-TRD patients (McIntyre et al., 2014) and even inconsistencies of findings (Shah et al., 2002; Zhou et al., 2011 ) that were sometimes driven by a region of interest approach. Based on a previous study by our group (Paillère Martinot et al., 2011) reporting higher fluoro-deoxyglucose metabolism (FDG) in the amygdala associated with decreased FDG in the orbitofrontal cortex in TRD patients resistant to repetitive transcranial magnetic stimulation, we searched for frontal-limbic structural abnormalities in TRD.
The purpose of our study was to compare patients with TRD or non-TRD, and healthy controls using whole-brain voxel-based morphometry (Ashburner & Friston 2000; Ridgway et al., 2008) of regional volumes.
METHODS
The local ethics committees (APHP Salpêtrière and Bicêtre hospitals) approved the protocol of the study and each participant provided written informed consent before inclusion in the studies.
Participants
We pooled datasets obtained from 125 participants enrolled in previous brain-imaging protocols. Detailed demographic and clinical characteristics have been reported elsewhere (Paillère Martinot et al., 2011; Penttila et al., 2009 ). Briefly, we recruited patients from consecutive admissions at an outpatient clinic and six psychiatry wards of university hospitals in Paris, France. Experienced senior psychiatrists established the patients' diagnoses using the DSM-IV and the MiniInternational Neuropsychiatric Interview. We also recruited healthy controls by word of mouth and enrolled them at the same time as the patients. They had no personal history of psychiatric or neurological disorders, as assessed by the Mini-International Neuropsychiatric Interview and a medical examination.
Treatment resistance was defined as the lack of response to at least two antidepressants from different pharmacologic classes taken for at least 1 month in adequate dosages (Berlim & Turecki, 2007) .
Non-TRD patients were in remission from a major depressive episode. Both unipolar and bipolar patients were considered in both TRD and non-TRD groups (Table 1) .
At the time of scan, most of the patients received treatment (74/81); they were taking antidepressant medications, anticonvulsants, lithium, antipsychotics, or benzodiazepines (Table 1 ). There were only three nonmedicated patients in the TRD group and four in the non-TRD group during data acquisition. 
Image acquisition

Voxel-based morphometry
Data were processed and examined using the Statistical Parametric Mapping software (SPM8, https://www.fil.ion.ucl.ac.uk/spm/software/ spm8/). To study the morphometric changes in the depression groups (responders and nonresponders to the treatment) versus controls, VBM was performed using the unified segmentation implemented in SPM8 (Ashburner & Friston, 2005) . T1-weighted images were spatially normalized and segmented using the "new segmentation" toolbox with the extended tissues probability maps. Afterward, VBM implemented in the VBM8 toolbox was applied (https://dbm.neuro. uni-jena.de/vbm8/) using clean-up segmentation and de-noising with nonlocal means filters for "write already estimated segmentation." Finally, the modulated GM images were smoothed with a Gaussian kernel of 10 mm full-width half-maximum (FWHM) isotropic Gaussian kernel. 
TA B L E 1 Demographic and medication characteristics for subjects with MDD and healthy controls
Statistics
Demographic and clinical variables were analyzed within JMP software (https://www.jmp.com) using ANOVA, Khi2, or t-tests as necessary.
Imaging data were analyzed using SPM8 software and General Linear model. Voxel-wise GM differences between the patient groups and controls were examined using one-way ANOVA. In order to answer to both primary and exploratory questions, the model included five groups (unipolar TRD, bipolar TRD, unipolar non-TRD, bipolar non-TRD, and healthy controls). Age, total intracranial volume (TIV), gender, voxel size, and the treatment (antidepressants, lithium, anticonvulsants used as mood stabilizers, antipsychotics, benzodiazepine) were entered in the analysis as covariates.
Primary analyses compared MDD (including TRD and non-TRD) patients versus controls, followed by TRD patients versus non-TRD patients. We also searched for differences between UP and BP TRD patients and between UP and BP non-TRD patients.
Secondary analyses explored the effect of treatments in the whole group of patients.
For all analyses, the height threshold was set at P < .001 and the extent threshold at P < 0.05 (600 voxels), with family-wise error (FWE) correction for multiple spatial comparisons at the cluster level across the whole brain.
RESULTS
Demographic and medication characteristics for subjects with MDD and healthy controls are reported in Table 1 . TRD patients had significantly higher depression scores (MADRS) than non-TRD patients. Also, the non-TRD patients were more likely to have bipolar depression.
No other between-group difference was found, particularly regarding medications.
Primary analyses
The whole MDD patient group (vs. control group) exhibited reduced GM volume in the right anterior cingulate (Table 2 ). Larger GM volume was found in bilateral amygdala in TRD patients as compared to non-TRD patients ( Figure 1 and Table 2) . No difference was found between UP and BP TRD patients nor between UP and BP non-TRD patients.
Secondary analyses
The patients on lithium showed larger GM volumes in superior and middle frontal gyri bilaterally when compared with patients not on lithium ( Figure 2 and Table 2 ).
No significant difference was found with the other treatments.
DISCUSSION
The comparison between patients with TRD and non-TRD motivated by the scarce information in the literature revealed a higher GM volume of the amygdala in the TRD patient group, whereas there was no difference in amygdala volumes between the whole depressed patient group and healthy controls. In addition, the greater amygdala volume in TRD patients was independent, irrespective of whether the patients presented bipolar or unipolar features. The depressed patients as a whole also exhibited reduced GM volume of the right anterior cingulate. The neurotrophic effect of the treatment with lithium was underlined once more by the current study showing higher GM volume in the superior and middle frontal gyri in the patients treated with lithium. Yucel et al., 2008) . The evidence for reductions in other regions within frontosubcortical and limbic regions is less consistently reported (Bora et al. 2012; Du et al., 2012) . The current comparison consolidates once more the association between MDD and reduced GM density in ACC and supports Drevets et al.'s (1997) conclusion that despite treatment with antidepressant medication, the reduction in subgenual ACC volume still persists.
TA B L E 2 Regional gray matter density differences in whole-brain voxel-based comparisons
TRD is modelled as a failure of brain homeostatic mechanisms; the frontal lobes would be less active, whereas the limbic regions, and notably the amygdala (involved in emotional processing and autonomic reactivity), would be overactive during depression (Giacobbe, Mayberg, & Lozano, 2009 ). Lui et al. (2011) found a higher connectivity in the TRD group with respect to the non-TRD within the left amygdalaanterior cingulate cortex-right insula-precuneus region. A seminal historical study (Hornig et al., 1997) among the few that did a direct comparison between the TRD and non-TRD is also consistent with our findings of higher hippocampus-amygdala blood flow in TRD than in non-TRD patients. Here, the direct comparison between non-TRD and TRD groups highlights the difference in amygdala volume.
Amygdala, which plays a crucial role in modulating human emotion (Hamilton, Siemer, & Gotlib, 2008) has been extensively investigated with neuroimaging in affective disorders. Reviews of the literature, however, report the most conflicting findings depending on the stage of the disorder (Bellani, Baiano, & Brambilla, 2011; Hamilton et al., 2008; Kubitz et al., 2013) . Only one VBM study in TRD patients has reported differences in amygdala volumes (Li et al., 2010) . The authors found, in line with our results, a larger GM volume in the right amygdala, in the nonremitting patients when compared with those who achieved remission, although at a lenient, uncorrected statistical threshold.
Differences in regional brain volumes have previously been hypothesized between patients able to achieve remission and those refractory to antidepressants. A study found atrophy in the right frontostriatal region in TRD, but the authors did not attempt to measure amygdala separately and the treatment status was not controlled between the TRD and non-TRD patient groups (Shah et al., 2002) .
In contrast with our results, Lorenzetti, Allen, Whittle, and
Yuecel (2010) found a larger left amygdala in non-TRD remitted MDD patients when compared to healthy controls, whereas other investigators showed a larger amygdala in the healthy control group when compared to MDD patients (Keller et al., 2008; Kronenberg et al., 2009) . Another study has shown smaller hippocampal volumes in TRD patients relative to controls contrasting with our results that show no difference (Joshi et al., 2016) . Interestingly, in this study, smaller hippocampal and larger amygdala volumes associated with response to subsequent ECT treatment, which further increased amygdala volume (Joshi et al., 2016; Ten Doesschate, van Eijndhoven, Tendolkar, van Wingen, & van Waarde, 2014) . Thus, the question arises whether changes in amygdala volume in MDD are a trait characteristic of the disease or are related to disease progression, chronicity, or medication.
Enlarged amygdala volumes have also been reported in first-episode depressed patients (van Eijndhoven et al., 2009) , with a positive correlation with the severity of depression. However, both increased (Frodl et al., 2002 (Frodl et al., , 2003 (Bora et al., 2012; Singh, DelBello, & Chang, 2012) .
Additionally, other factors that might influence amygdala volume include comorbid anxiety (Caetano et al., 2007) and medication, particularly mood stabilizers that are supposed to exert a neurotrophic effect (Price & Drevets 2010; Savitz et al., 2010) . Meta-analytical studies by Hamilton et al. (2008) and Price and Drevets (2010) have indicated that studies focusing on only nonmedicated depressed patients showed significantly lower amygdala volume in the depressed group when compared with controls, whereas studies in which all depressed patients were receiving adequate medication showed significantly larger amygdala volumes in the depressed group (Weniger, Lange, & Irle, 2006) .
A particularity in the present study is that both groups (TRD and non-TRD) received treatment and one could hypothesize that the treatment received by TRD during recurrent episodes of illness may have had a cumulative neurotrophic effect reflected through a larger amygdala, even if the clinical features had not significantly improved.
However, ongoing medication was included here as a covariate in the statistical analysis; thus, it is unlikely that the findings would relate to medication only.
Furthermore, the finding of our exploratory comparison in patients (TRD and non-TRD) treated with lithium versus patients without lithium advocates against a unique effect of medication on the amygdala volumes. We observed a higher GM volume in the superior and middle frontal gyri bilaterally in patients with lithium. Moore et al.
(2009) also found a significant increase in GM volume in the prefrontal cortex related to lithium treatment. These results emphasize the purported neurotrophic effect of lithium (Quiroz, Machado-Vieira, Zarate, & Manji, 2010) , notably on the prefrontal cortex. However, the neurotrophic effect of lithium in the present study did not account for the higher GM volume in amygdala, as the comparison of lithium and nonlithium-treated patients did not yield results in these regions.
Given the heterogeneous nature of depression (Wager & Woo, 2017) , it is possible that other factors that were not studied in our
work may yet influence findings. For example, some recent work (Drysdale et al., 2017; Wager & Woo, 2017) has shown that distinct depression connectivity biotypes may determine treatment responsiveness. Also, disease course (age of onset, number of depressive episodes) may contribute to variations in brain morphology. However, in our study, no relation was found between age of onset or duration of illness and amygdala volume.
Still, a main limitation of the present study is that it cannot disentangle whether the larger amygdala volume relates to vulnerability or develops through the course of the disease. Indeed, the cross-sectional design of the study makes it difficult to determine whether a larger volume indicates a risk factor for TRD from the onset of illness, or whether it is a consequence of the failure of brain homeostatic mechanisms (e.g., overactive amygdala) related to comorbid anxiety during depression.
Also, patients with bipolar and unipolar depression were pooled in this study. Differences in amygdala volumes might have blurred the results, as larger amygdala volumes have been reported in adults with bipolar disorder (Strakowski, 2012) , whereas reduced amygdala volumes have been found in adolescent patients with bipolar disorder (Pfeifer, Welge, Strakowski, Adler, & DelBello, 2008) . In the present study, however, there was no difference between the TRD BP patients and the TRD UP patients, and no difference between the non-TRD UP and BP patients, indicating a similar pattern regarding amygdala volumes in UP and BP patients.
CONCLUSIONS
Overall, this study found that TRD patients exhibit larger GM amygdala volumes. This increase was not related to medication or to bipolar or unipolar status, and might provide a neuroimaging biomarker of vulnerability to chronicity, revealed by medication resistance. 
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